Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06937086 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Study acronym: COMMIT-UC
StatusRecruiting
PhasePhase 3
Started2025-06-26
View on ClinicalTrials.gov ↗
The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment.

Amendment record

Amended 26 times since 2025-04-18; most recent filed 2026-08-20. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-08-20
Amendment Study Status, Contacts/Locations v26
2026-08-05
Amendment Study Status, Contacts/Locations v25
2026-07-17
Amendment Study Status, Contacts/Locations v24
2026-07-03
Amendment Study Status, Contacts/Locations v23
2026-06-19
Amendment Study Status, Contacts/Locations v22
2026-06-02
Amendment Study Status, Contacts/Locations v21
2026-05-11
Amendment Study Status, Contacts/Locations v20
2026-04-16
Amendment Study Status, Contacts/Locations v19
2026-03-22
Amendment Study Status, Contacts/Locations v18
2026-03-05
Amendment Study Status, Contacts/Locations v17
2026-02-27
Amendment Study Status, Contacts/Locations v16
2026-02-09
Amendment Study Status, Contacts/Locations v15
2026-01-16
Amendment Study Status, Contacts/Locations v14
2026-01-12
Amendment Study Status, Contacts/Locations v13
2025-12-17
Amendment Study Status, Contacts/Locations v12
2025-12-02
Amendment Study Status, Outcome Measures, Contacts/Locations v11
2025-11-19
Amendment Study Status, Contacts/Locations v10
2025-11-03
Amendment Study Status, Contacts/Locations v9
2025-10-15
Amendment Study Status, Contacts/Locations v8
2025-10-08
Amendment Study Status, Contacts/Locations v7
2025-09-25
Amendment Study Status, Contacts/Locations v6
2025-09-08
Amendment Study Status, Contacts/Locations v5
2025-08-25
Amendment Study Status, Contacts/Locations v4
2025-07-22
Amendment Study Status, Contacts/Locations v3
2025-07-02
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
2025-05-30
Amendment Study Status, Contacts/Locations, References v1
2025-04-18
Original filing
Trial Details
NCT Number NCT06937086
Lead Sponsor Eli Lilly and Company
Conditions Ulcerative Colitis, Obesity or Overweight
Enrollment 350 participants
Start Date 2025-06-26
Primary Completion 2028-04 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-09-04